Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. (Q38616563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

title

Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

Paul M O'Byrne

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

author name string

A I El-Gammal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

18 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

38-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

The global burden of asthma: executive summary of the GINA Dissemination Committee report

28 February 2020

cites work

1 reference

7 January 2021

Failure in asthma control: reasons and consequences

1 reference

7 January 2021

IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways

1 reference

7 January 2021

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

7 January 2021

The passive transfer of allergy.

1 reference

7 January 2021

An investigation into IgE-facilitated allergen recognition and presentation by human dendritic cells

1 reference

7 January 2021

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

1 reference

7 January 2021

IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis.

1 reference

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

7 January 2021

Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents

1 reference

7 January 2021

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

1 reference

7 January 2021

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

7 January 2021

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

1 reference

7 January 2021

After 6 years with Xolair; a 3-year withdrawal follow-up

1 reference

7 January 2021

Safety and tolerability of omalizumab

1 reference

7 January 2021

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

1 reference

7 January 2021

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

1 reference

7 January 2021

Omalizumab and the risk of malignancy: results from a pooled analysis

1 reference

7 January 2021

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab

1 reference

7 January 2021

The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy

1 reference

7 January 2021

1 reference

7 January 2021

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

1 reference

7 January 2021

The IL-4 receptor: signaling mechanisms and biologic functions

1 reference

7 January 2021

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

1 reference

7 January 2021

Interleukin-4 and interleukin-13 signaling connections maps

1 reference

7 January 2021

IL-4 and IL-13 signaling in allergic airway disease

1 reference

7 January 2021

Dupilumab in persistent asthma with elevated eosinophil levels

1 reference

7 January 2021

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

7 January 2021

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

7 January 2021

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

1 reference

7 January 2021

Lebrikizumab Treatment in Adults with Asthma

1 reference

7 January 2021

Periostin promotes chronic allergic inflammation in response to Th2 cytokines.

1 reference

7 January 2021

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

1 reference

7 January 2021

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

1 reference

7 January 2021

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

1 reference

7 January 2021

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

1 reference

7 January 2021

Anti-IL5 therapy for asthma and beyond

1 reference

7 January 2021

The role of interleukin-5 (IL-5 ) in vivo: studies with IL-5 deficient mice

1 reference

7 January 2021

Effect of Inhaled Interleukin-5 on Airway Hyperreactivity and Eosinophilia in Asthmatics

1 reference

7 January 2021

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

7 January 2021

The trials and tribulations of IL-5, eosinophils, and allergic asthma

1 reference

7 January 2021

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

7 January 2021

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

7 January 2021

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

7 January 2021

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

1 reference

7 January 2021

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

1 reference

7 January 2021

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

7 January 2021

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

7 January 2021

1 reference

7 January 2021

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

1 reference

7 January 2021

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

7 January 2021

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

1 reference

7 January 2021

Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9)

1 reference

7 January 2021

Th9: a new player in asthma pathogenesis?

1 reference

7 January 2021

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma

1 reference

7 January 2021

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

1 reference

7 January 2021

Role of IL-23 and Th17 Cells in Airway Inflammation in Asthma

1 reference

7 January 2021

Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines.

1 reference

7 January 2021

Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells

1 reference

7 January 2021

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma

1 reference

7 January 2021

Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma

1 reference

7 January 2021

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

1 reference

7 January 2021

IL-23 and Th17 Cells Enhance Th2-Cell–mediated Eosinophilic Airway Inflammation in Mice

1 reference

7 January 2021

Silencing IL-23 expression by a small hairpin RNA protects against asthma in mice

1 reference

7 January 2021

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses

1 reference

7 January 2021

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis.

1 reference

7 January 2021

Interleukin 25 in allergic airway inflammation

1 reference

7 January 2021

IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo

1 reference

7 January 2021

Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma

1 reference

7 January 2021

IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma.

1 reference

7 January 2021

Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma

1 reference

7 January 2021

Interleukin-33 - cytokine of dual function or novel alarmin?

1 reference

7 January 2021

IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G

1 reference

7 January 2021

IL-33 mediates inflammatory responses in human lung tissue cells

1 reference

7 January 2021

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

1 reference

7 January 2021

Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling

1 reference

7 January 2021

Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells

1 reference

7 January 2021

Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma.

1 reference

7 January 2021

Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice

1 reference

7 January 2021

Interleukin (IL)-33: new therapeutic target for atopic diseases.

1 reference

7 January 2021

Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma

1 reference

7 January 2021

The alarmin IL-33 promotes regulatory T-cell function in the intestine

1 reference

7 January 2021

Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease.

1 reference

7 January 2021

Thymic stromal lymphopoietin: a central regulator of allergic asthma

1 reference

7 January 2021

TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling.

1 reference

7 January 2021

Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice

1 reference

7 January 2021

Human metapneumovirus infection activates the TSLP pathway that drives excessive pulmonary inflammation and viral replication in mice.

1 reference

7 January 2021

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses

1 reference

7 January 2021

Role of TNFalpha in pulmonary pathophysiology

1 reference

7 January 2021

Evidence of a role of tumor necrosis factor alpha in refractory asthma

1 reference

7 January 2021

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma

1 reference

7 January 2021

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial

1 reference

7 January 2021

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

1 reference

7 January 2021

Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation

1 reference

7 January 2021

Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma

1 reference

7 January 2021

A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria

1 reference

7 January 2021

Eculizumab for treatment of asthma

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPT.284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26502193 AND SRC:MED&resulttype=core&format=json

28 February 2020

1 reference